The place of early haemoperfusion with polymyxin B fibre column in the treatment of sepsis.
Direct haemoperfusion with polymyxin B-immobilized fibre (PMX-F) is a promising treatment for Gram-negative sepsis in critically ill patients. Indeed, it has been used routinely in Japan for a decade. Recent evidence presented in this journal suggests that PMX-F can have a positive impact on outcome in patients with sepsis, although other reports in the literature have presented confusing or even conflicting results. This commentary considers whether the available evidence allows us to establish an appropriate role for PMX-F treatment in sepsis and what further work is needed.
Ronco
Claudio
C
Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006464:Hemoperfusion / Q000295:instrumentation* / Q000379:methods* / Q000639:trends; D006801:Humans; D018579:Patient Selection; D011112:Polymyxin B / Q000627:therapeutic use*; D018805:Sepsis / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D011112:Polymyxin B